background: recently, the use of t7 rna polymerase instead of other viral and cellular promoters is increasing due to high efficacy of transcription in the cell cytoplasm by this polymerase. in order to translate the transcripts produced by t7 rna polymerase in mammalian cell lines, it is necessary to include internal ribosome entry site (ires) sequences. in addition, if sequence of poly a sign...

Abstract: Background  and  Aims:  Huh-7  is  a  cell  line  that  was  derived  from  a  liver  tumor  of  a  Japanese  man.  Hepatocellular  carcinoma  (HCC)  is  considered  as  a  primary  liver  cancer.  Highly  resistant  tumor  to  treatment  which  causes  the  death  of  many  patients  annually.  Thus,  targeting  the  cancer  cells  by  using  a  new  method  could  be  effective  in...

new cancer therapies with novel mechanisms and functions are needed to treat patients with different cancers. virotherapy is a good scenario for such treatment. the advantages of virotherapy include the potential lack of cross resistance with standard therapies and the ability to cause tumor destruction by numerous mechanisms. oncolytic virus not only possesses unique mechanisms of action that ...

Oncolytic viruses show specific targeting and killing of tumor cells and therefore provide attractive assets for cancer immunotherapy. In parallel to oncolytic viral vectors based on adenoviruses and herpes simplex viruses, oncolytic RNA viruses and particularly alphaviruses have been evaluated as delivery vehicles. Immunization studies in experimental rodent models for various cancers includin...

Oncolytic viruses consist of a diverse range of DNA and RNA viruses traditionally thought to mediate their effects by exploiting aberrations in tumor pathways, allowing preferential viral replication in, and killing of, tumor cells. Clinical development has progressed to late-phase trials, potentially heralding their introduction into clinical practice. However, despite this promise, the activi...

The development of oncolytic viruses has led to an emerging new class of cancer therapeutics. Although the safety profile has been encouraging, the transition of oncolytic viruses to the clinical setting has been a slow process due to modifications. Therefore, a new generation of more potent oncolytic viruses needs to be exploited, following our better understanding of the complex interactions ...

conclusions this study delineated the beneficial role of rsv for growth regulation of skin cancer cells and highlighted the involvement of rsv in the induction of apoptosis in a431 cells. these findings might conduct evidence into the oncolytic properties of rsv in the skin cancer. further studies are required to indicate intracellular targets for rsv-induced apoptosis in skin cancer cells. res...

Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and well-tolerated therapies for this deadly disease. The use of oncolytic viruses has garnered significant interest as cancer therapeutics in recent years, an...

Experimental evolution has been used for various biotechnological applications including protein and microbial cell engineering, but less commonly in the field of oncolytic virotherapy. Here, we sought to adapt a rapidly evolving RNA virus to cells deficient for the tumor suppressor gene p53, a hallmark of cancer cells. To achieve this goal, we established four independent evolution lines of th...

Vesicular stomatitis virus (VSV) is a promising oncolytic agent against a variety of cancers. However, it has never been tested in any pancreatic cancer model. Pancreatic ductal adenocarcinoma (PDA) is the most common and aggressive form of pancreatic cancer. In this study, the oncolytic potentials of several VSV variants were analyzed in a panel of 13 clinically relevant human PDA cell lines a...